|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reeder JG and Vogel VG: Breast cancer risk
management. Clin Breast Cancer. 7:833–840. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan PH and Lota AS: Interaction of current
cancer treatments and the immune system: Implications for breast
cancer therapeutics. Expert Opin Pharmacother. 9:2639–2660. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anderson KS: Tumor vaccines for breast
cancer. Cancer Invest. 27:361–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carson WE III and Liang MI: Current
immunotherapeutic strategies in breast cancer. Surg Oncol Clin N
Am. 16:841–860, ix. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: Moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Curigliano G, Spitaleri G, Dettori M,
Locatelli M, Scarano E and Goldhirsch A: Vaccine immunotherapy in
breast cancer treatment: Promising, but still early. Expert Rev
Anticancer Ther. 7:1225–1241. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ostrand-Rosenberg S and Sinha P:
Myeloid-derived suppressor cells: Linking inflammation and cancer.
J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zea AH, Rodriguez PC, Atkins MB, Hernandez
C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A,
O'Neill A, et al: Arginase-producing myeloid suppressor cells in
renal cell carcinoma patients: A mechanism of tumor evasion. Cancer
Res. 65:3044–3048. 2005.PubMed/NCBI
|
|
11
|
Ochoa AC, Zea AH, Hernandez C and
Rodriguez PC: Arginase, prostaglandins, and myeloid-derived
suppressor cells in renal cell carcinoma. Clin Cancer Res.
13:721s–726s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kusmartsev S, Nefedova Y, Yoder D and
Gabrilovich DI: Antigen-specific inhibition of CD8+ T cell response
by immature myeloid cells in cancer is mediated by reactive oxygen
species. J Immunol. 172:989–999. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Solito S, Falisi E, Diaz-Montero CM, Doni
A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P,
Onicescu G, et al: A human promyelocytic-like population is
responsible for the immune suppression mediated by myeloid-derived
suppressor cells. Blood. 118:2254–2265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Almand B, Clark JI, Nikitina E, van Beynen
J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased
production of immature myeloid cells in cancer patients: A
mechanism of immunosuppression in cancer. J Immunol. 166:678–689.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mosmann TR, Cherwinski H, Bond MW, Giedlin
MA and Coffman RL: Two types of murine helper T cell clone. I.
Definition according to profiles of lymphokine activities and
secreted proteins. J Immunol. 136:2348–2357. 1986.PubMed/NCBI
|
|
16
|
Shibata M, Nezu T, Kanou H, Abe H,
Takekawa M and Fukuzawa M: Decreased production of interleukin-12
and type 2 immune responses are marked in cachectic patients with
colorectal and gastric cancer. J Clin Gastroenterol. 34:416–420.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Diaz-Montero CM, Salem ML, Nishimura MI,
Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating
myeloid-derived suppressor cells correlate with clinical cancer
stage, metastatic tumor burden, and doxorubicin-cyclophosphamide
chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bevers TB, Anderson BO, Bonaccio E, Buys
S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE,
et al: NCCN clinical practice guidelines in oncology: Breast cancer
screening and diagnosis. J Natl Compr Canc Netw. 7:1060–1096. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Le HK, Graham L, Cha E, Morales JK,
Manjili MH and Bear HD: Gemcitabine directly inhibits myeloid
derived suppressor cells in BALB/c mice bearing 4T1 mammary
carcinoma and augments expansion of T cells from tumor-bearing
mice. Int Immunopharmacol. 9:900–909. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonda K, Shibata M, Nakamura I, Kenjo A,
Ohtake T, Yasuda M, Suzuki S, Suzuki H, Watanabe T, Fujimori K, et
al: Myeloid-derived suppressor cells in cancer patients. Gan To
Kagaku Ryoho. 39:1797–1799. 2012.(In Japanese). PubMed/NCBI
|
|
21
|
Markowitz J, Wesolowski R, Papenfuss T,
Brooks TR and Carson WE III: Myeloid-derived suppressor cells in
breast cancer. Breast Cancer Res Treat. 140:13–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thakur A, Schalk D, Sarkar SH, Al-Khadimi
Z, Sarkar FH and Lum LG: A Th1 cytokine-enriched microenvironment
enhances tumor killing by activated T cells armed with bispecific
antibodies and inhibits the development of myeloid-derived
suppressor cells. Cancer Immunol Immunother. 61:497–509. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Steding CE, Wu ST, Zhang Y, Jeng MH, Elzey
BD and Kao C: The role of interleukin-12 on modulating
myeloid-derived suppressor cells, increasing overall survival and
reducing metastasis. Immunology. 133:221–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sinha P, Clements VK, Fulton AM and
Ostrand-Rosenberg S: Prostaglandin E2 promotes tumor progression by
inducing myeloid-derived suppressor cells. Cancer Res.
67:4507–4513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Panis C, Lemos LG, Victorino VJ, Herrera
AC, Campos FC, Simão AN Colado, Pinge-Filho P, Cecchini AL and
Cecchini R: Immunological effects of taxol and adryamicin in breast
cancer patients. Cancer Immunol Immunother. 61:481–488. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gonda K, Shibata M, Ohtake T, Yasuda M,
Abe N, Watanabe K, Ando J, Okano M, Onozawa H, Tachibana K, et al:
Myeloid-derived suppressor cells in patients with breast cancer.
Gan To Kagaku Ryoho. 39:1363–1368. 2012.(In Japanese). PubMed/NCBI
|
|
27
|
Diaz-Montero CM, Finke J and Montero AJ:
Myeloid-derived suppressor cells in cancer: Therapeutic,
predictive, and prognostic implications. Semin Oncol. 41:174–184.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Emens LA: Breast cancer immunobiology
driving immunotherapy: Vaccines and immune checkpoint blockade.
Expert Rev Anticancer Ther. 12:1597–1611. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de Coaña Y Pico, Masucci G, Hansson J and
Kiessling R: Myeloid-derived suppressor cells and their role in
CTLA-4 blockade therapy. Cancer Immunol Immunother. 63:977–983.
2014. View Article : Google Scholar : PubMed/NCBI
|
